We are live on ! Find out more
GC

Gratry & Company Portfolio holdings

AUM $72.2M
1-Year Est. Return 19.87%
This Fund
S&P 500
This Quarter Est. Return
-3.77%
1 Year Est. Return
+19.87%
3 Year Est. Return
+44.17%
5 Year Est. Return
+89.51%
10 Year Est. Return
–
AUM
$305M
AUM Growth
+$114M
Cap. Flow
+$94.3M
Cap. Flow %
30.9%
Top 10 Hldgs %
32.27%
Holding
83
New
22
Increased
37
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$11M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.37M
3
SI
SIEMENS AKTIENGESELLSCHAFT ADS
SI
+$8.42M
4
AZ
Allianz Se Sponsored Adr Repstg 1/10 Ord Sh
AZ
+$8.16M
5
WX
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
+$7.27M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$6.66M
2
ICLR icon
Icon
ICLR
+$6.45M
3
SLB icon
SLB Ltd
SLB
+$5.93M
4
PUK icon
Prudential
PUK
+$5.36M
5
NVO
Novo Nordisk
NVO
+$4.86M

Sector Composition

Rank Sector Weight
1 Financials 18.58%
2 Healthcare 18.22%
3 Industrials 11.69%
4 Consumer Discretionary 7.34%
5 Technology 6.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESRX
51
DELISTED
Express Scripts Holding Company
ESRX
$555K 0.18%
7,900
+1,410
+22% +$110K
COST icon
52
Costco
COST
$429B
$473K 0.15%
3,970
+260
+7% +$35.3K
UNP icon
53
Union Pacific
UNP
$175B
$444K 0.15%
2,645
-2,570
-49% -$295K
AAPL icon
54
Apple
AAPL
$4.99T
$435K 0.14%
3,104
-18,664
-86% -$508K
SYK icon
55
Stryker
SYK
$133B
$336K 0.11%
4,475
+562
+14% +$49.9K
JPM icon
56
JPMorgan Chase
JPM
$950B
$334K 0.11%
5,715
– –
TTE icon
57
TotalEnergies
TTE
$187B
$334K 0.11%
5,452
– –
BRFS
58
DELISTED
BRF SA
BRFS
$311K 0.1%
+14,925
New +$365K
MMM icon
59
3M
MMM
$94.1B
$304K 0.1%
2,589
+293
+13% +$37.6K
NMR icon
60
Nomura Holdings
NMR
$28.1B
$90K 0.03%
+11,590
New +$68.6K
BIDU icon
61
Baidu
BIDU
$35.7B
– –
-13,200
Closed -$2.88M
GILD icon
62
Gilead Sciences
GILD
$167B
– –
-4,685
Closed -$499K
HCA icon
63
HCA Healthcare
HCA
$92.8B
– –
-8,315
Closed -$586K
ICLR icon
64
Icon
ICLR
$13.9B
– –
-112,780
Closed -$6.45M
MA icon
65
Mastercard
MA
$497B
– –
-7,890
Closed -$583K
PNR icon
66
Pentair
PNR
$10.8B
– –
-101,513
Closed -$4.46M
PUK icon
67
Prudential
PUK
$36.1B
– –
-124,179
Closed -$5.36M
RIO icon
68
Rio Tinto
RIO
$149B
– –
-94,790
Closed -$4.66M
SLB icon
69
SLB Ltd
SLB
$74.2B
– –
-58,300
Closed -$5.93M
SWKS icon
70
Skyworks Solutions
SWKS
$9.73B
– –
-8,135
Closed -$472K
TRN icon
71
Trinity Industries
TRN
$3.03B
– –
-23,446
Closed -$789K
URI icon
72
United Rentals
URI
$67.9B
– –
-2,845
Closed -$316K
VIPS icon
73
Vipshop
VIPS
$7.13B
– –
-97,700
Closed -$1.85M
AGN
74
DELISTED
Allergan plc
AGN
– –
-27,595
Closed -$6.66M
1 2
3

Similar funds

T
Tahithromos New York $71.9M AUM 0.24% 1-Year Est. Return
DCM
Delpha Capital Management New York $72.9M AUM
XS
XML Securities Bethesda, Maryland $80.6M AUM
BSCP
Bay Street Capital Partners New York $81.9M AUM
SCM
Stonerise Capital Management San Francisco, California $62.6M AUM 1.3% 1-Year Est. Return
FMA
FNY Managed Accounts New York $83.4M AUM 11.55% 1-Year Est. Return
MSTVIM
Messner & Smith Theme Value Investment Management San Diego, California $60.3M AUM 16.8% 1-Year Est. Return
LA
Lucus Advisors New York $57.7M AUM 0.6% 1-Year Est. Return

Gratry & Company's Q4 2014 Portfolio in Review

As of Q4 2014, Gratry & Company held 83 positions worth $305M, up 60% from $191M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Gratry & Company deployed $94.3M of net new capital in Q4 2014, opening 22 new positions and adding to 37 existing holdings. Its largest new stake was COVIDIEN PLC COM SHS NEW (IRELAND): 114,152 shares worth $7.77M.

By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 10% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Novo Nordisk, an estimated $4.86M trimmed.

  • Gratry & Company's largest Q4 2014 buy was COVIDIEN PLC COM SHS NEW (IRELAND): 114,152 shares worth $7.77M.
  • Gratry & Company added most to Jazz Pharmaceuticals in Q4 2014, an estimated $9.37M increase.
  • Gratry & Company's biggest Q4 2014 reduction was Novo Nordisk, cutting an estimated $4.86M.
  • Gratry & Company fully exited Allergan plc in Q4 2014, selling an estimated $6.66M.
  • Gratry & Company's ten largest holdings make up 32% of its $305M portfolio in Q4 2014.
  • Gratry & Company opened 22 new positions and closed 14 in Q4 2014.
  • Gratry & Company's portfolio value rose 60% quarter-over-quarter to $305M.

Based on Gratry & Company's 13F filing for Q4 2014, filed 18 Feb 2015.